




RealRate

PHARMACEUTICAL 2020

Brooklyn ImmunoTherapeutics Inc.
Rank 92 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Brooklyn ImmunoTherapeutics Inc. Rank 92 of 362



The relative strengths and weaknesses of Brooklyn ImmunoTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Brooklyn ImmunoTherapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 594% points. The greatest weakness of Brooklyn ImmunoTherapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 191% points.

The company's Economic Capital Ratio, given in the ranking table, is -22%, being 281% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	6,070
Cost of Goods Sold	0
Intangible Assets	696
Liabilities, Current	6,095
Liabilities, Non-Current	2,917
Other Assets	4,537
Other Compr. Net Income	68
Other Expenses	8,420
Other Liabilities	22
Other Net Income	-258
Property and Equipment	2,822
Research and Development	0
Revenues	19,806
Selling, General and Administrative Expense	13,175

Output Variable	Value in 1000 USD
Assets	14,125
Liabilities	9,034
Expenses	21,595
Stockholders Equity	5,091
Net Income	-2,047
Comprehensive Net Income	-2,013
Economic Capital Ratio	-22%

